Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads to humoral immune response against SARS-CoV-2, which is comparable to that according to a homologous mRNA vaccination scheme

Ruben Rose 1,†, Franziska Neumann 2,†, Olaf Grobe 2, Thomas Lorentz 2, Helmut Fickenscher 1, Andi Krumbholz 1, 2,*

1 Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
2 Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany

* Correspondence: krumbholz@infmed.uni-kiel.de; Tel.: +49-431-22010131
† These first authors contributed equally

Abstract

Background: The humoral immune response after primary immunisation with a SARS-CoV-2 vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost (BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody response after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2).

Methods: Sera from 59 vaccinees were tested for SARS-CoV-2 immunoglobulin G (IgG) and virus-neutralising antibodies (VNA) with four IgG assays, a surrogate neutralisation test (sVNT) and a Vero cell-based neutralisation test (cVNT) before and after heterologous (n=31 and 42) or homologous booster vaccination (AZD1222/AZD1222, n=8/9; BNT162b2/BNT162b2, n=8/8). The strength of IgG binding to separate SARS-CoV-2 antigens was measured as avidity.

Results: After the first vaccination, prevalence of IgGs antibodies directed against (trimeric) SARS-CoV-2 spike (S)- protein and its receptor-binding domain (RBD) varied from 55-95 % (AZD1222) to 100% (BNT162b2), depending on the vaccine used and the SARS-CoV-2 antigen used. The booster vaccination resulted in 100 percent seroconversion and appearance of highly avid IgG as well as VNA against a SARS-CoV-2 variant of concern (alpha; B.1.1.7) used as antigen in the cVNT. The results of the sVNT basically agree with those of our in-house cVNT, but the sVNT seems to overestimate non- and weakly virus-neutralizing titres. The mean IgG and VNA titres were higher after heterologous vaccination compared to the homologous AZD1222 scheme.

Conclusions: The heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-SARS-CoV-2 IgG and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination scheme. Irrespectively of the chosen immunisation regime, highly avid IgG antibodies can be detected just two weeks after the second vaccine dose indicating the development of a robust humoral immunity.

Keywords: COVID-19; vaccination schemes; immunoglobulin G; maturity process; virus-neutralisation

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Background

Since spring 2020 the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] is ongoing and represents a global challenge. The availability of safe and effective vaccinations are seen as one of the most important pillars in containing the pandemic [2, 3]. Within a few months, the intensive research activities led to the development of several highly effective SARS-CoV-2 vaccines [4, 5, 3]. In addition to the induction of cellular immunity, their administration should stimulate the formation of virus-neutralising antibodies (VNA) that bind to epitopes of the viral spike (S) protein and its receptor binding domain (RBD) and, thus, prevent the cells from being infected [6, 7, 3].

Four SARS-CoV-2 vaccines have received conditional approval in the European Union. These vaccines are based on two different technologies [8]. For the messenger ribonucleic acid (mRNA) vaccines from Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), the genetic information for the S-protein was genetically optimized and the mRNA was packaged in liposomes. After inoculation, the muscle cells directly expressed this stable and highly immunogenic viral surface protein [2, 6]. In vector vaccines, replication-deficient human (Ad26.COV2; Janssen) or chimpanzee adenoviruses (ChAdOx1 nCoV-19/AZD1222, Vaxzevria; AstraZeneca, hereinafter referred to as AZD1222) are used to introduce the genetic information of the SARS-CoV-2 S-protein into the cells, followed by transcription of deoxyribonucleic acid into mRNA and expression of the S-protein [2, 6].

Due to the widespread use of these vaccines, rare and sometimes unexpected side effects have been reported. Particularly noteworthy are cases of immune thrombotic thrombocytopenia, which predominantly occurred in women under 50 years of age within one month after the initial vaccination with AZD1222 [5]. Many of these patients developed cerebral sinus venous thrombosis or splanchnic vein thrombosis and presented antibodies to platelet factor 4 but without previous exposure to heparin [5]. Due to this rare but serious side effect, AZD1222 is no longer unreservedly recommended by the Standing Vaccination Commission (STIKO) of the Robert Koch Institute for individuals under 60 years of age. The STIKO suggests that a vaccination with AZD1222 that has already started should be completed with an mRNA vaccine [9, 10]. Due to the sharp increase in the delta variant (Pango lineage [11] B.1.617.2) in Germany, the STIKO has revised its recommendations once more. Since July 1st 2021, all AZD1222 first vaccinated persons have been recommended to complete the second vaccination with an mRNA vaccine [12]. Animal experiments indicated very good humoral and cellular immunity after heterologous vaccination [13, 14]. There is, however, so far only little knowledge on the benefit of the heterologous vaccination scheme in humans. First results indicated a higher prevalence of short-lived side effects following the heterologous boost dose compared to the homologous counterpart [15]. Only a few and mostly preliminary results have so far been published for the immunogenicity of the AZD1222 / mRNA vaccine regimen [16-19].

In this study, we compare the SARS-CoV-2 specific immunoglobulin G (IgG) response after heterologous immunisation with that elicited by homologous vaccination schedules. We also focus on the developing anti-SARS-CoV-2 IgG avidity as a parameter for IgG maturity and binding strength.
Finally, we use various methods to investigate the development of VNA. Therefore, humoral immunity induced by vaccines is being extensively studied. We believe that the results obtained in this study will help to better understand the effects and possibly benefits of a heterologous vaccination regimen.

Methods

The anti-S and anti-RBD IgG response after heterologous immunisation with a SARS-CoV-2 vector vaccine as prime and an mRNA vaccine as boost was compared to that after homologous vaccination with vector or mRNA vaccines. This setting also includes monitoring of IgG avidity and of virus-neutralizing capacities. Forty-seven female and twelve male vaccinees with a median age of 31 years (age span 18 – 61 years) were recruited for this study and gave their informed consent. Forty-two of them received a heterologous immunisation scheme (N=41, AZD1222/BNT162b2; N=1, AZD1222/mRNA-1273), while nine and eight vaccinees received a homologous scheme of the vector vaccine AZD1222 or the mRNA vaccine BNT162b2, respectively. The first blood sample was taken at a median of 68 days after initial vaccination and the second sample was taken at a median of 15 days after the second immunisation. For several individuals no serum was available before or after the booster vaccination (Table 1). The ethics committee of the medical faculty of the Christian-Albrechts-Universität zu Kiel (Kiel, Germany) approved the study design (D467/20, 16.04.2020, amendment 02.02.2021). We examined the early humoral immune response (other samples obtained a few days to weeks after the initial immunisation with AZD1222) of most of the subjects in a previous study. In addition, sera obtained from three vaccinees after the initial immunisation with BNT162b2 (N=2) and AZD1222 (N=1) have already been tested in frame of the previous study [20]. In this respect, we consider it justified to include these individuals (and few sera) in the present report and to demonstrate the results before and after the booster vaccination.

Anti-SARS-CoV-2 specific IgG immunoassays

The sera were tested with the SERION ELISA agile SARS-COV-2 IgG assay (S-protein as antigen; Institut Virion\Serion GmbH, Würzburg, Germany) and the Abbott SARS-CoV-2 IgG II Quant assay (RBD as antigen; Abbott, Wiesbaden, Germany) as described previously [20]. In addition, the LIAISON® SARS-CoV-2 Trimeric S IgG assay was included as a further assay on a LIAISON® XL system (both Diasorin S.p.A, Saluggia, Italy). According to the manufacturer, this quantitative chemiluminescence immunoassay detects IgG directed against the trimeric S-protein and has an excellent clinical sensitivity and specificity of 98.7% and 99.5%, respectively. The high diagnostic value of this test has also been demonstrated in a recent seroprevalence study [21]. The results of the three IgG assays were given in Binding Antibody Units (BAU) per milliliter (BAU / ml), using the manufacturer’s conversion factors, which were based on measurements of the WHO International Standard Anti-SARS-CoV-2 Immunoglobulin (NIBSC code 20-136) [22]. As in our previous studies, we generally rate borderline test results as positive [23, 20].

Anti-SARS-CoV-2 IgG immunoblots including measurement of IgG avidities
All sera were tested with and without avidity reagent in the recomLine SARS-CoV-2 IgG assay (Mikrogen GmbH, Neuried, Germany) as reported previously [23, 20]. The strength of SARS-CoV-2 antigen binding against the S1-and RBD-subunits of the S-protein and against the nucleoprotein (NP, if detectable) was assigned to the categories low (= 1), intermediate (= 2), and high (= 3) [20].

**Measurement of SARS-CoV-2-neutralising antibodies with two different assays**

The sera were examined for their virus-neutralising capacities. First, a surrogate assay was used (TECO® SARS-CoV-2 Neutralisation Antibody ELISA; TECOmedical AG, Sissach, Switzerland). In this competitive assay, the human angiotensin-converting enzyme 2 (ACE-2) was attached to the solid phase while peroxidase-conjugated RBD was present in the liquid phase. If the human serum contained RBD-specific antibodies, binding of RBD to ACE-2 was prevented. Hence, after washing steps the color reaction turned out to be weaker compared to a RBD-antibody-free serum sample. According to the manufacturer, it is assumed from an inhibition of 20% that VNA are present.

Second, dilutions of each serum were tested in triplicate in a laboratory-developed Vero cell-based neutralisation assay (cVNT). This 96-well format cVNT uses an own B.1.1.7 strain from January 2021 as antigen. A dilution >1:10 was considered likely protective [23, 20].

**Data evaluation and statistical calculations**

Data were statistically analysed by help of the GraphPad Prism version 9.1.2 software (GraphPad Software, San Diego, CA, USA). We generally used the Kruskal-Wallis test, an adjusted, non-paired and non-parametric test. The significance level was defined as 0.05. Furthermore, we calculated the Pearson correlation coefficient r to demonstrate the linear correlation between separate data sets. We used simple logistic regression to determine the probability of detecting VNA with our cVNT as a function of sVNT results.

**Results**

**Composition of the study groups**

This study included 59 individuals. Nine and eight of them received a homologous vaccination with AZD1222 or BNT162b2, respectively, while 42 received a heterologous vaccination. The composition of the study groups including median age, age-span, gender and time span of blood sampling is presented in Table 1.
Table 1. Individuals included in this study

<table>
<thead>
<tr>
<th>Study groups</th>
<th>Number of individuals after 1st/2nd vaccination</th>
<th>Median age in years</th>
<th>Age span in years</th>
<th>Gender (female/male)</th>
<th>Time span from 1st/2nd vaccination to 1st/2nd serum sampling in days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heterologous vaccination scheme</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZD1222/BNT162b2</td>
<td>30/41</td>
<td>27</td>
<td>18-56</td>
<td>33/8</td>
<td>69/16</td>
</tr>
<tr>
<td>AZD1222/mRNA-1273</td>
<td>1/1</td>
<td>45</td>
<td>45-45</td>
<td>1/0</td>
<td>64/14</td>
</tr>
<tr>
<td>Homologous vaccination scheme</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZD1222</td>
<td>8/9</td>
<td>41</td>
<td>23-61</td>
<td>6/3</td>
<td>34/14</td>
</tr>
<tr>
<td>BNT162b2</td>
<td>8/8</td>
<td>35</td>
<td>23-51</td>
<td>7/1</td>
<td>34/14</td>
</tr>
</tbody>
</table>

After the first immunisation, all individuals who received an mRNA vaccine developed anti-(trimeric)-S and anti-RBD-IgG. The vaccinees who received the AZD1222 had a prevalence of 55.3 % (anti-S IgG), 76.3 % (anti-trimeric S IgG) and 94.7 % (anti-RBD IgG), respectively. After administration of the second dose, the IgG prevalence reached 100% in all groups. The mean anti-SARS-CoV-2 IgG titres varied between 39.9 BAU/ml (anti-S IgG; first vaccination in the AZD1222/mRNA group) to 6584 BAU/ml (anti-trimeric S IgG; second vaccination in the BNT162b2/BNT162b2 group). After the second vaccine dose, an increase in mean anti-SARS-CoV-2 titres was observed in all three study groups and in all assays. Compared to the mean anti-SARS-CoV-2 IgG titres after the vector vaccine AZD1222 was administered twice, the corresponding titres were 7 to 10 times higher after a heterologous vaccination and even 10 to 15 times higher according to the homologous BNT162b2 vaccination scheme (Figure 1).
Figure 1: Anti-SARS-CoV-2 immunoglobulin G response after first (1; empty circles) and second (2; filled circles) immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or mRNA-1273. The cut-offs for positivity (including borderline results) of anti-trimeric spike (S) IgG assay (A), of the anti-S IgG assay (B), and of the anti-RBD IgG assay (C), respectively, are marked by dashed lines. Ns: non-significant; *: p < 0.05; **: p < 0.01; ****: p < 0.0001 (adjusted non-paired and non-parametric test; Kruskal-Wallis test).

Next, we examined the development of anti SARS-CoV-2 IgG avidity in an immunoblot. After the first vaccination, the mean avidity index was in the low to intermediate range. In contrast, high avidities were consistently observed after administration of the second vaccine dose (Figure 2). None of the vaccinees showed an IgG reactivity against the NP in the immunoblot (data not shown).
Figure 2: Development of anti-SARS-CoV-2 immunoglobulin G avidities after first (1; empty circles) and second (2; filled circles) immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or mRNA-1273. The measured IgG avidities were assigned to the three categories low (1), intermediate (2) and high (3). Ns: non-significant; *: p < 0.05; **: p < 0.01; ****: p < 0.0001 (adjusted non-paired and non-parametric test; Kruskal-Wallis test).

The virus-neutralising properties of the sera were examined with two different assays. A so-called surrogate neutralisation test was used to investigate the extent to which the anti-RBD antibodies that may be present in the serum are able to prevent the binding of this S-protein subunit to the human receptor ACE2. In addition, a laboratory-developed virus-neutralisation test was used, which is based on a B.1.1.7 strain as the antigen. While the majority of the sera in the sVNT were already to be regarded as neutralizing after the first vaccination, these samples did not yet show any corresponding properties in the cVNT. With both methods, however, an increase in the level of VNA could be detected after a second vaccination. There were also marked differences between the three vaccination groups, both in the degree of inhibition (sVNT) and in the level of VNA titres (cVNT). Vaccinees who had received the vector vaccine only had 13- and 11-fold lower geometric mean VNA titres (1:47) compared to individuals immunised heterologously with AZD1222 / mRNA (1:608) or homologously with BNT162b2 (1:538), respectively. However, the mean % inhibition of sVNT reached about the same level in all three groups (Figure 3). Even though the quantitative results correlate with a Pearson correlation coefficient r of 0.84 well in both tests, it is noticeable that especially non-neutralising sera (≤1:10) are overestimated in the sVNT. This is evidenced by the fact that the cut-off set by the manufacturer is only associated with a 4 % probability of detecting VNA in our cVNT (Figure 4).
Figure 3: Development of SARS-CoV-2 neutralising antibodies (VNA) after first (1; empty circles) and second (2; filled circles) immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or mRNA-1273. A surrogate neutralisation assay (A) and a Vero-cell based virus-neutralisation test (B) using a B.1.1.7 strain were used to measure the VNAs. The assay cut-offs are indicated by dashed lines. Ns: non-significant; *: p < 0.05; **: p < 0.01; ****: p < 0.0001 (adjusted non-paired and non-parametric test; Kruskal-Wallis test).

Figure 4: Correlation of the surrogate neutralisation test (sVNT) results with results obtained by the laboratory developed Vero-cell based virus-neutralisation test (cVNT) using a B.1.1.7 strain as antigen (A). The Pearson correlation coefficient r of log(reciprocal titre) was calculated with 0.84; empty circles; first vaccination; filled circles: second vaccination; red: heterologous vaccination with AZD1222/mRNA; green: homologous vaccination with AZD1222; blue: homologous vaccination with BNT162b2. Probability of detecting virus-neutralising antibodies (VNA) with the in-house cVNT at a given % inhibition of sVNT calculated by logistic regression (B); e.g. at 20% inhibition (black dashed line), 63% inhibition (red dashed line), and at 85% inhibition of sVNT (red dashed line), the probabilities of detecting VNA with cVNT are 4% (95%CI 1%-16%), 50% (95%CI 34%-66%) and 83% (95%CI 70%-91%), respectively.
Due to the rare but serious side effects after administration of the vector vaccine, in spring 2021 the STIKO recommended that people under the age of 60 should complete vaccinations that had already been started with a vector vaccine with an mRNA vaccine [9, 10]. This recommendation was extended on July 1st, 2021 to all who had already received a primary vaccination with AZD1222 [12]. In the first quarter of this year, however, only a few animal experimental data were available on the immunological outcome of the proposed heterologous vaccination scheme [13, 14]. Several preprints have now appeared on the immunogenicity of the heterologous vaccination scheme in humans [16-19].

We took this general knowledge gap as an opportunity to compare the development of the humoral immune response after homologous and heterologous vaccination.

After the first vaccination, the majority of vaccinees developed anti-trimeric-S, -S, and -RBD IgG antibodies, respectively. However, their titres varied between the three study groups. The results are in line with our previous study [20]. It is evident that the anti-SARS-CoV-2 IgG titres are not comparable between the three assays either. This is probably due to the different antigen preparations. In this respect, from our point of view, titre comparisons are only possible if they have been measured with the same assay.

The second vaccination resulted in higher titres in all three groups. It was noticeable that significantly higher anti-SARS-CoV-2 IgG titres were detected after a second vaccination with an mRNA vaccine than after the vector vaccine AZD1222 was administered again. The increase in anti-S and anti-RBD IgG titres after a second vaccination with an mRNA vaccine confirms our previous study. Due to the recommended vaccination interval of 10 to 12 weeks, we did not yet have any data on the development of the SARS-CoV-2-specific IgG antibodies after the second administration of a vector vaccine [20]. The absence of NP-specific IgG antibodies in all vaccinated persons can be interpreted as a hint that they have not had a SARS-CoV-2 infection and were therefore to be regarded as immunologically naive before the vaccination [20]. It is known that vaccinations lead to particularly high anti-SARS-CoV-2 IgG titres in convalescents [24]. For these individuals, the recommendation is that they should receive a vaccine dose about six months after they have been infected [10].

After the first vaccination nearly all vaccinees exhibited only low to intermediate avid anti-SARS-CoV-2 IgG, while after the second vaccine dose IgG of high avidity appeared in all cases. In line with this, VNA > 1:10 against the prevalent VOC B.1.1.7 strain were observed after second vaccination. The results confirm our previous study [20]. Marked differences in the level of VNA titres were observed between individuals re-vaccinated with an mRNA vaccine and those re-vaccinated with a vector vaccine which is in accordance to previous animal experiments [13]. Basically, the sVNT also showed the titre increase and evaluated all sera as virus-neutralizing after the second vaccination. However, it is again noticeable that sera that are not or only weakly virus-neutralising in the in-house cVNT are already evaluated as neutralising in the sVNT. This result underscores our previous suggestion to raise the cut-off of the sVNT [20]. Compared to the admittedly very conservative in-house cVNT, a cut-off of
over 80% would be desirable. Due to the lack of standardisation of the widespread cVNTs for the
detection of VNA against SARS-CoV-2, this recommendation only applies to our laboratory and cannot
be generalised.

The data presented by us on the humoral immune response after heterologous SARS-CoV-2
vaccination are consistent with the few available clinical studies [16, 18, 17, 19]. A recent preprint
reports significant higher anti-S-antibody titres in a group of 26 individuals who first received an
AZD1222 vaccination followed by re-vaccination with BNT162b2 compared to 14 individuals that were
vaccinated twice with BNT162b2. These results were obtained with a total antibody assay which does
not discriminate between IgG and acute phase immunoglobulin M. Nearly four-fold higher virus-
neutralising titres were observed in the AZD1222/BNT162b2 group using a chimeric vesicular
stomatitis virus carrying the S-protein of SARS-CoV-2 VOC B.1.1.7 as antigen. However, data after
homologous vaccination with the vector vaccine are missing in this study [16]. We also observe
differences in the titre level of the VNA in the cVNT. However, these are not to be regarded as
significant in every case.

In another preprint [18], differences in the anti-S IgG and VNA titres were not observed after
heterologous vaccination (AZD1222/mRNA) or after homologous vaccination with an mRNA vaccine.
In contrast, both parameters were significantly lower after homologous vaccination with the vector
vaccine [18]. These results are in agreement with our data even if only one IgG assay and one sVNT
were used by this research group.

The results of a previously non-peer reviewed single-blind randomised British study, in which the four
possible vaccine combinations of AZD1222 and BNT162b2 were compared with one another, are very
interesting and promising. These researchers report about 9-fold higher mean anti-S IgG titres in
heterologous AZD1222/BNT162b2 vaccinees compared to individuals immunized twice with AZD1222
[19] which is largely in accordance to our results.

Only one preprint investigates the development of IgG avidity after heterologous SARS-CoV-2
vaccination in humans [17]. Therein the immune response after heterologous vaccination was
compared with that after homologous vaccination with an mRNA vaccine. However, results obtained
after homologous vaccination with a vector vaccine are missing. The authors demonstrate comparable
IgG responses after the booster vaccination and an increase in VNA (determined by sVNT) as well as
of IgG avidity [17], which is in line to our data and to results of animal experiments [13].

It is not yet sufficiently clear why homologous vaccination with the AZD1222 vector vaccine leads to
lower anti-SARS-CoV-2 IgG and VNA titres. A possible explanation could be the immune response to
the adenovirus vector backbone (so called “antivector immunity” [3]).

The work presented by us contributes to a better understanding of the humoral immunogenicity of
the heterologous SARS-CoV-2 vaccination regimen. With various assays we monitored the
development of anti S-specific IgG antibodies and make statements about their binding-strength as an
expression of maturity. In addition, with a commercial and an in-house test, we showed that VNA can
be detected after the second vaccination. Important limitations of our report are (i) the heterogeneity
of the study groups, (ii) the small group size of individuals who received a homologous vaccination scheme, (iii) the subjects, who are predominantly in younger to middle adulthood, (iv) the lack of information on the durability of the detected antibodies, and (v) the missing consideration of cellular and innate immunity after immunisation. Therefore, among other things, no statements can be made from our data about the need for further booster vaccinations. In addition, no better protection against SARS-CoV-2 infections can be derived from the level of the antibody titre per se.

In summary, the combination of a first vaccination with a vector vaccine followed by a second administration of an mRNA vaccine leads to a strong humoral immune response, comparable to that achieved after two vaccinations with an mRNA vaccine. Regardless of the vaccination schedule, all individuals develop highly avid anti-SARS-CoV-2 IgGs and VNA shortly after the second vaccination.
Availability of data: The data presented in this study are available on request from the corresponding author.

Ethics approval and consent to participate: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the medical faculty of the Christian-Albrechts-Universität zu Kiel, Kiel, Germany (D467/20, 16.04.2020; amendment 02.02.2021). Informed consent was obtained from all subjects involved in the study.

Consent for publication: Not applicable.

Competing interests: The companies Diasorin GmbH, Mikrogen GmbH and Tecomedical GmbH supported this study by providing free or discounted kits. None of the three companies had any influence on the testing and the interpretation of the results. The authors declare that they have no competing interests.

Author Contributions: AK, FN, and RR had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: AK. Acquisition, analysis, or interpretation of the data: all authors. Drafting of the manuscript: AK, HF and RR. Critical revision of the manuscript for important intellectual content: all authors. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: The authors would like to thank all subjects for participating in the study.


References


